{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma%2C+Uveal&page=2", "query": { "condition": "Melanoma, Uveal", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma%2C+Uveal&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T23:24:51.650Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01665183", "title": "Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors" ], "interventions": [ { "name": "ADI-PEG 20", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Polaris Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2012-09", "completion_date": "2016-02", "has_results": false, "last_update_posted_date": "2016-02-25", "last_synced_at": "2026-06-10T23:24:51.650Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01665183" }, { "nct_id": "NCT05308901", "title": "Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma, Uveal" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2022-08-02", "completion_date": "2027-06", "has_results": true, "last_update_posted_date": "2025-07-25", "last_synced_at": "2026-06-10T23:24:51.650Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05308901" }, { "nct_id": "NCT02068586", "title": "Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ciliary Body and Choroid Melanoma, Medium/Large Size", "Ciliary Body and Choroid Melanoma, Small Size", "Iris Melanoma", "Stage I Intraocular Melanoma", "Stage IIA Intraocular Melanoma", "Stage IIB Intraocular Melanoma", "Stage IIIA Intraocular Melanoma", "Stage IIIB Intraocular Melanoma", "Stage IIIC Intraocular Melanoma", "Stage I Uveal Melanoma AJCC V7", "Stage II Uveal Melanoma AJCC V7", "Stage III Uveal Melanoma AJCC V7" ], "interventions": [ { "name": "Sunitinib", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" }, { "name": "Sunitinib Malate + Valproic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2014-11-19", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-06-10T23:24:51.650Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02068586" }, { "nct_id": "NCT05077280", "title": "A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uveal Melanoma" ], "interventions": [ { "name": "stereotactic body radiotherapy", "type": "RADIATION" }, { "name": "Immunotherapy", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "California Pacific Medical Center Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2021-09-20", "completion_date": "2026-03", "has_results": false, "last_update_posted_date": "2022-12-06", "last_synced_at": "2026-06-10T23:24:51.650Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05077280" }, { "nct_id": "NCT00351728", "title": "Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ocular Melanoma", "Choroidal Melanoma", "Uveal Melanoma" ], "interventions": [], "intervention_types": [], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 174, "start_date": "2006-06", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2016-07-07", "last_synced_at": "2026-06-10T23:24:51.650Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00351728" }, { "nct_id": "NCT02029690", "title": "Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pleural Mesothelioma Malignant Advanced", "Peritoneal Mesothelioma Malignant Advanced", "Non-squamous Non-small Cell Lung Carcinoma", "Uveal Melanoma", "Hepatocellular Carcinoma", "Glioma", "Sarcomatoid Carcinoma" ], "interventions": [ { "name": "ADI-PEG 20", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Polaris Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2014-04-23", "completion_date": "2020-06", "has_results": false, "last_update_posted_date": "2020-09-25", "last_synced_at": "2026-06-10T23:24:51.650Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02029690" }, { "nct_id": "NCT00085306", "title": "Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IV Melanoma", "Recurrent Melanoma" ], "interventions": [ { "name": "recombinant interferon beta", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2004-04", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2015-10-02", "last_synced_at": "2026-06-10T23:24:51.650Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085306" }, { "nct_id": "NCT00499733", "title": "Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Cryoablation", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 19, "start_date": "2007-06", "completion_date": "2013-01-09", "has_results": false, "last_update_posted_date": "2019-01-18", "last_synced_at": "2026-06-10T23:24:51.650Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499733" }, { "nct_id": "NCT05266430", "title": "Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Choroidal Melanoma", "Indeterminate Lesions" ], "interventions": [ { "name": "Standard of Care", "type": "OTHER" }, { "name": "AU-011", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Aura Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2022-04-14", "completion_date": "2023-04-20", "has_results": false, "last_update_posted_date": "2023-08-09", "last_synced_at": "2026-06-10T23:24:51.650Z", "location_count": 7, "location_summary": "Royal Oak, Michigan • Portland, Oregon • Greenville, South Carolina + 4 more", "locations": [ { "city": "Royal Oak", "state": "Michigan" }, { "city": "Portland", "state": "Oregon" }, { "city": "Greenville", "state": "South Carolina" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Bellaire", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05266430" }, { "nct_id": "NCT05585034", "title": "Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Melanoma Excluding Uveal Melanoma", "Non-small Cell Lung Cancer, Squamous or Non-squamous", "Urothelial Carcinoma", "Renal Cell Carcinoma, Clear Cell", "Castration-resistant Prostate Cancer", "Ovarian Cancer, Epithelial", "TNBC - Triple-Negative Breast Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "XmAb®808", "type": "BIOLOGICAL" }, { "name": "Keytruda® (pembrolizumab)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2022-12-14", "completion_date": "2025-05-20", "has_results": false, "last_update_posted_date": "2025-08-07", "last_synced_at": "2026-06-10T23:24:51.650Z", "location_count": 12, "location_summary": "Los Angeles, California • Denver, Colorado • Sarasota, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05585034" } ] }